Pierrel Past Earnings Performance
Past criteria checks 4/6
Pierrel has been growing earnings at an average annual rate of 7.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 4.4% per year. Pierrel's return on equity is 12.1%, and it has net margins of 11.5%.
Key information
7.3%
Earnings growth rate
-17.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 4.4% |
| Return on equity | 12.1% |
| Net Margin | 11.5% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pierrel makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 27 | 3 | 7 | 0 |
| 31 Mar 23 | 25 | 1 | 7 | 0 |
| 31 Dec 22 | 24 | 1 | 7 | 0 |
| 30 Sep 22 | 25 | 1 | 7 | 0 |
| 30 Jun 22 | 24 | 2 | 7 | 0 |
| 31 Mar 22 | 23 | 3 | 7 | 0 |
| 31 Dec 21 | 24 | 3 | 7 | 0 |
| 30 Sep 21 | 21 | 3 | 6 | 0 |
| 30 Jun 21 | 19 | 1 | 6 | 0 |
| 31 Mar 21 | 21 | 3 | 6 | 0 |
| 31 Dec 20 | 18 | 2 | 6 | 0 |
| 30 Sep 20 | 20 | 3 | 6 | 0 |
| 30 Jun 20 | 23 | 4 | 6 | 0 |
| 31 Mar 20 | 21 | 2 | 6 | 0 |
| 31 Dec 19 | 22 | 2 | 6 | 0 |
| 30 Sep 19 | 22 | 1 | 6 | 0 |
| 30 Jun 19 | 21 | 1 | 6 | 0 |
| 31 Mar 19 | 21 | 1 | 6 | 0 |
| 31 Dec 18 | 20 | 1 | 6 | 0 |
| 30 Sep 18 | 21 | 2 | 6 | 0 |
| 30 Jun 18 | 20 | 2 | 6 | 0 |
| 31 Mar 18 | 19 | 0 | 5 | 0 |
| 31 Dec 17 | 17 | -3 | 5 | 0 |
| 30 Sep 17 | 15 | -8 | 5 | 0 |
| 30 Jun 17 | 14 | -9 | 5 | 0 |
| 31 Mar 17 | 14 | -8 | 5 | 0 |
| 31 Dec 16 | 15 | -6 | 5 | 0 |
| 30 Sep 16 | 14 | -2 | 6 | 0 |
| 30 Jun 16 | 14 | -1 | 6 | 0 |
| 31 Mar 16 | 15 | 0 | 6 | 0 |
| 31 Dec 15 | 16 | 0 | 6 | 0 |
| 30 Sep 15 | 5 | 10 | -2 | 0 |
| 30 Jun 15 | 8 | 6 | 0 | 0 |
| 31 Mar 15 | 13 | 0 | 3 | 0 |
| 31 Dec 14 | 15 | -2 | 6 | 0 |
| 30 Sep 14 | 30 | -16 | 17 | 0 |
| 30 Jun 14 | 29 | -16 | 17 | 0 |
| 31 Mar 14 | 29 | -12 | 17 | 0 |
| 31 Dec 13 | 30 | -13 | 17 | 0 |
| 30 Sep 13 | 30 | -14 | 18 | 0 |
| 30 Jun 13 | 36 | -12 | 18 | 0 |
| 31 Mar 13 | 40 | -13 | 19 | 0 |
| 31 Dec 12 | 42 | -11 | 19 | 0 |
Quality Earnings: 0FP4 has a large one-off gain of €741.2K impacting its last 12 months of financial results to 30th June, 2023.
Growing Profit Margin: 0FP4's current net profit margins (11.5%) are higher than last year (7.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0FP4 has become profitable over the past 5 years, growing earnings by 7.3% per year.
Accelerating Growth: 0FP4's earnings growth over the past year (75.3%) exceeds its 5-year average (7.3% per year).
Earnings vs Industry: 0FP4 earnings growth over the past year (75.3%) exceeded the Pharmaceuticals industry -41.9%.
Return on Equity
High ROE: 0FP4's Return on Equity (12.1%) is considered low.